| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
MEIP Stock Overview
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
MEI Pharma, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.54 |
| 52 Week High | US$3.55 |
| 52 Week Low | US$0.41 |
| Beta | 0.85 |
| 1 Month Change | -4.76% |
| 3 Month Change | 16.04% |
| 1 Year Change | -79.47% |
| 3 Year Change | -67.81% |
| 5 Year Change | -78.92% |
| Change since IPO | -99.88% |
Recent News & Updates
Shareholder Returns
| MEIP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 8.6% | 1.8% | 4.5% |
| 1Y | -79.5% | -22.2% | -8.9% |
Return vs Industry: MEIP underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: MEIP underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| MEIP volatility | |
|---|---|
| MEIP Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 12.5% |
| Market Average Movement | 7.6% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MEIP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MEIP's weekly volatility (12%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 76 | Dan Gold | https://www.meipharma.com |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. Fundamentals Summary
| MEIP fundamental statistics | |
|---|---|
| Market Cap | US$72.43m |
| Earnings (TTM) | -US$46.77m |
| Revenue (TTM) | US$36.74m |
2.0x
P/S Ratio-1.5x
P/E RatioIs MEIP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MEIP income statement (TTM) | |
|---|---|
| Revenue | US$36.74m |
| Cost of Revenue | US$0 |
| Gross Profit | US$36.74m |
| Other Expenses | US$83.51m |
| Earnings | -US$46.77m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 100.00% |
| Net Profit Margin | -127.31% |
| Debt/Equity Ratio | 0% |
How did MEIP perform over the long term?
See historical performance and comparison